Background The efficacy and safety of vedolizumab in bio-naïve patients with ulcerative
colitis (UC) and Crohn's disease (CD) remain unknown. Aims To perform a meta-analysis …

The number of patients with inflammatory bowel disease (IBD) approaching an older age,
together with the number of over-60-year-old patients newly diagnosed with IBD, is steadily …

Background Vedolizumab registration trials were the first to include elderly patients with
moderate‐to‐severe ulcerative colitis (UC) or Crohn's disease (CD), but few real‐life data …

Abstract Background and Aims Many observational studies on the use of vedolizumab [VDZ]
in patients with Crohn's disease [CD] and ulcerative colitis [UC] have been published in the …

Abstract Background and Aims Clinical trials and real-life studies with ustekinumab in
Crohn's disease [CD] have revealed a good efficacy and safety profile. However, these data …

ABSTRACT Introduction Vedolizumab (Entyvio) is a humanized monoclonal antibody that
disrupts the interaction between α4β7 integrin on circulating T-lymphocytes and MAdCAM-1 …

The incidence and prevalence of inflammatory bowel disease (IBD) is rising in the elderly
population. Compared with patients with onset during their younger years, patients with …

Background Anti-tumour necrosis factor (anti-TNF) agents are associated with increased
infection risk among elderly inflammatory bowel disease (IBD) patients, and thus, alternative …

Background: Inflammatory bowel diseases are immune-mediated disorders that include
Crohn's disease (CD) and ulcerative colitis (UC). UC is a progressive disease that affects the …

Abstract Background and Aim: Newer biologics appeared safer in landmark clinical trials,
but their safety is understudied in vulnerable populations. The aim of the present study was …